


J.P.Morgan

Q3 2026 Biopharma Licensing and Venture Report

October 2026

Fueled by



Executive summary

Biopharma venture funding slowed in Q3 but is still positioned for annual growth, while year-to-date M&A and IPO totals surpassed 2025

Biopharma financing and transaction activity remained strong through Q3 2026, with venture funding easing after a robust second quarter. The sector benefited from an open IPO window, investor receptiveness to reverse mergers, and elevated M&A. Public-market performance in Q3 was muted, as the XBI’s YTD gains were largely driven by the first half of the year.

Licensing remained substantial and milestone-heavy. M&A value moderated in Q3, but year-to-date activity already exceeded full-year 2025 in dollar terms. IPO proceeds and offering counts have also surpassed each annual total from 2022 through 2025.

Here are a few highlights from our Q3 2026 report:

- **Venture funding:** Biopharma venture funding totaled \$23.9 billion across 385 rounds in 2026 YTD, including \$6.7 billion in Q3, down from \$9.9 billion in Q2.
- **Licensing:** R&D licensing value reached an announced \$221.1 billion in 2026 YTD, with upfront cash representing 6% of total deal value.
- **M&A:** Biopharma M&A totaled \$138.9 billion of up-front cash across 113 deals in 2026 YTD, including \$31.1 billion across 32 deals in Q3.
- **IPOs:** Biopharma IPOs raised \$7.5 billion across 22 offerings in 2026 YTD, exceeding each full-year total from 2022 through 2025 in both proceeds and deal count.

J.P. Morgan is dedicated to your success. Our relationships, our capital and our skilled team of bankers and specialists dedicated to the life sciences and healthcare sectors reflect our conviction in the pivotal contributions these clients add to their stakeholders—society, shareholders and employees alike.

Our bankers’ expertise ranges from advising companies at the earliest stage of formation to the most graduated, complex M&A and capital markets transactions. Regardless of the size or stage of your company, we are prepared, equipped and enthusiastic about advising and enabling you to meet your strategic, financial and technical objectives.

Thank you for taking the time to read this report. We look forward to supporting you.

Kathryn McDonough
Managing Director, Head of Life Sciences
Innovation Economy, Commercial Banking
J.P. Morgan

Contributor
Dan Greaney, CFA
Executive Director, Life Sciences
Innovation Economy, Commercial Banking
J.P. Morgan

Contributor
Elena Lovo, PhD
Executive Director, Head of Life Sciences EMEA
Innovation Economy, Global Corporate Banking
J.P. Morgan

Parameters

Biopharma companies are defined as firms developing therapeutics and technology platforms engaged in drug discovery, clinical R&D and commercialization.


Therapy areas, development stages, modalities and deal structures are segmented per the DealForma database.

Financials are based on disclosed figures curated by DealForma. Multiple tranches of the same series are counted as one.


Data as of Sept. 30, 2026

Biopharma venture funding slowed in Q3 after a strong second quarter

QUARTERLY BIOPHARMA VENTURE INVESTMENT VS. ANNUAL VENTURE DEAL COUNT¹



10-YEAR U.S. TREASURY YIELD VS. BIOPHARMA VENTURE DEPLOYMENT (INDEXED)^{1,2}



Biopharma venture funding totaled \$23.9 billion across 385 rounds through Q3 2026. Q3 funding totaled \$6.7 billion, broadly in line with Q3 2025, it declined 33% from Q2 2026, the strongest quarter since Q1 2022.

Despite the weaker third quarter, 2026 remains on pace to surpass 2025. At the current run rate, full-year funding is projected to reach approximately \$33 billion, exceeding the \$30.5 billion raised in 2025. Reaching that estimate would require a stronger Q4 than Q3 but would mark four consecutive years of growth in venture capital deployed.

The biopharma capital deployment index declined to 110.9 in Q3 as the 10-year U.S. Treasury yield rose above 5%. Even so, capital deployment remains above its pre-2020 baseline, suggesting investor appetite for biopharma innovation remains intact despite a more challenging financing environment.

Notes: ¹Financials based on disclosed figures. Data through Sept. 30, 2026. ²Biopharma venture capital deployment is indexed to Q1 2020, where Q1 2020=100.

Market indices traded sideways in Q3 while XBI retained YTD outperformance

3Y PRICE HISTORY – XBI BIOTECH ETF, S&P 500, AND NASDAQ (INDEXED)¹



Year to date, the SPDR S&P Biotech ETF (XBI) has outperformed the broader market. Through Q3, XBI rose 29.6%, compared with 14.7% for the Nasdaq and 10.9% for the S&P 500.

In Q3 2026, all three indices were largely flat over the 90-day period, with XBI down less than 1% while the Nasdaq and S&P 500 each rose slightly more than 2%.


Stronger public biotech performance in 2026 YTD coincided with an improved IPO market, with proceeds and offering counts exceeding each annual total from 2022 through 2025.

As of this writing, the Cboe Volatility Index (VIX) stood at 15.3. Readings below 20 are generally considered more conducive to public-market transactions.


Note:¹ XBI, S&P 500, and Nasdaq are indexed to Q3 2023, where Q3 2023=100. Data through Sept. 30, 2026.

Large venture rounds and \$100M+ licensing upfronts remained active through Q3

COUNT OF VENTURE INVESTMENT ROUNDS BY ROUND SIZE¹



COUNT OF BIOPHARMA R&D LICENSES BY DISCLOSED UPFRONT CASH AMOUNT¹



Biopharma venture funding included 68 rounds of \$100 million or more and 80 rounds between \$50 million and \$99 million in 2026 YTD.

Some of the larger Q3 2026 venture financings include Encoded Therapeutics' \$275 million Series F and Solstice Oncology's \$225 million Series A.

Through Q3, 35 R&D licensing deals disclosed upfront cash payments of \$100 million or more, compared with 46 deals in full-year 2025.


The largest collaboration deal of the quarter was a joint venture between CSPC Pharmaceutical Group and AstraZeneca, with \$1.2 billion upfront on total deal value of \$18.5 billion.

In another example of Big Pharma's partnership activity with Chinese biopharma firms, Novo Nordisk entered into an R&D collaboration with Hengrui Pharma for \$300 million upfront.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026.

Later-stage rounds captured nearly three-quarters of biopharma venture capital

BIOPHARMA SEED AND SERIES A VENTURE ACTIVITY VS. SERIES B+ VENTURE ACTIVITY¹



Biopharma companies raised \$23.9 billion across 385 rounds through Q3 2026. Series B and later financings accounted for \$17.3 billion across 215 rounds, representing about 72% of capital deployed and 56% of round activity.


Seed and Series A companies raised \$6.6 billion across 170 rounds. While early-stage investment remains active, capital remains concentrated in later-stage companies, where larger financings account for a disproportionate share of total funding.

Notable Q3 later-stage rounds included LifeMine Therapeutics' \$188 million Series E and Claris Biotherapeutics' \$118 million Series B. First-time financings totaled \$1.7 billion in Q3, their lowest quarterly level since Q3 2025.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026.

Median round sizes remained highest for Phase II and Phase III companies

BIOPHARMA THERAPEUTICS AND PLATFORMS: MEDIAN VENTURE ROUND SIZE BY COMPANY STAGE AT FUNDING¹



Median venture round size generally increased with clinical maturity in 2026 YTD, ranging from \$23 million for platform and discovery companies to \$57 million for Phase II companies and \$56 million for Phase III companies.


Phase II companies saw the strongest year-over-year expansion, with the median round increasing nearly 30% from \$44 million in 2025 to \$57 million in 2026 YTD. The cohort also included 23 rounds of at least \$100 million, highlighting continued investor support for companies with advancing clinical programs.

Earlier-stage medians were more measured. Platform and discovery round sizes declined to \$23 million, while preclinical and Phase I medians held broadly steady at \$26 million and \$38 million, respectively.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026.

U.S. attracted more than two-thirds of global biopharma funding

BIOPHARMA VENTURE INVESTMENT BY GEOGRAPHY, 2025 TO Q3 2026¹



From 2025 through Q3 2026, biopharma companies raised \$54.5 billion across 959 rounds globally. U.S.-based companies attracted \$37.2 billion across 537 rounds, or about 68% of total capital deployed.


The San Francisco Bay Area and Boston remained the leading U.S. biopharma hubs, raising \$12.8 billion and \$10.2 billion, respectively. Together, the two markets captured about 62% of U.S. funding over the period, underscoring the continued concentration of capital in established life-sciences ecosystems.

Through Q3 2026, the Bay Area raised \$6.2 billion, approaching the \$6.6 billion raised in full-year 2025. Boston attracted \$4.7 billion, compared with \$5.5 billion in 2025. San Diego, Philadelphia and the Research Triangle (Raleigh-Durham, N.C.) collectively raised another \$5.2 billion from 2025 through Q3 2026.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026.

European biopharma funding moderated, with the U.K. remaining the largest hub

BIOPHARMA VENTURE INVESTMENT BY GEOGRAPHY, 2025 TO Q3 2026¹



In Q3 2026, European biopharma companies raised \$1.1 billion, compared with \$584 million in Q3 2025) across 31 funding rounds.

The U.K. remained the largest European hub at \$380 million raised in Q3 2026, accounting for 34% of the \$1.1 billion raised and 26% of the 31 rounds. Switzerland followed at \$185 million (17%) across four rounds (13%), followed by the Netherlands at \$126 million (11%) across two rounds (6%) and Denmark at \$77 million (7%) across one round (3%). The remaining capital was raised across France, Sweden, Germany, Italy, Spain, Finland and Belgium, totaling \$348 million (31%) across 16 rounds (52%).

Across Europe, the \$1.1 billion raised in Q3 2026 was concentrated primarily in preclinical and Phase II assets and, by therapeutic area, in oncology. By technology, small molecules attracted the largest share of funding.


In Q3 2026, funding remained concentrated in fewer, larger rounds, with 50% (\$550 million) of total capital raised across five rounds, representing 16% of all financings (32 rounds).

Notable Q3 2026 funding rounds included Vaderis Therapeutics’ \$152 million Series B, Kynexis’ \$110 million Series A and R1 Therapeutics’ \$81 million Series A.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026.

Biopharma licensing remained elevated, supported by milestone-heavy structures

BIOPHARMA THERAPEUTICS AND PLATFORMS R&D LICENSING TOTALS AND UPFRONT CASH AS A PROPORTION OF DEAL VALUE¹



Biopharma R&D licensing value reached \$221.1 billion in announced totals through Q3 2026, representing about 81% of the record \$274.3 billion reported in full-year 2025.


Disclosed upfront cash represented 6% of total announced value, slightly below the 7% recorded in each of the prior three years and tied with 2022 for the lowest share shown since 2017. The data suggest deal structures remain weighted toward milestone-based and other contingent payments.

With one quarter remaining, 2026 licensing value is positioned to finish above most historical years, though matching 2025 would require about \$53 billion in additional announced value during Q4.


Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026.

Biologics led early-stage funding; genomics and small molecules active in licensing

TOP BIOPHARMA MODALITIES: TOTAL SEED AND SERIES A VENTURE FUNDING¹



TOP BIOPHARMA MODALITIES: TOTAL LICENSING UPFRONT CASH AND EQUITY¹



Biologics remained the largest modality for both seed and Series A funding and licensing upfront cash and equity in 2026 YTD, attracting \$2.5 billion in seed and Series A funding and \$4.4 billion in disclosed licensing upfront cash and equity.


Small molecules ranked second in early-stage venture funding at \$1.5 billion, while genomics, sequencing and screening ranked second in licensing upfronts at \$3 billion. Genomics licensing upfronts through Q3 were above the \$682 million disclosed in full-year 2025.

Although funding and licensing upfronts generally remained below 2025 totals, 2026 figures cover only the first three quarters. The modality mix suggests continued interest across established biologics and small-molecule approaches, alongside selective strength in genomics licensing.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026.

Big Pharma paid higher upfronts for later-stage assets through Q3 2026

IN-LICENSING BY BIG PHARMA: MEDIAN UPFRONT CASH & EQUITY AND NUMBER OF DEALS BY STAGE AT SIGNING¹



Median upfront cash and equity generally increased with asset maturity in 2026 YTD, reaching \$363 million for Phase II assets and \$450 million for Phase III assets. However, these medians reflect limited activity, with only two Phase II deals and three Phase III deals signed.


Earlier-stage licensing remained broader. Platform and discovery-stage assets accounted for 57 deals, with median upfront consideration rising to \$59 million, while preclinical activity totaled 11 deals with a median upfront consideration of \$75 million.

Phase I activity was also selective, with five deals and median upfront consideration of \$185 million. Overall, the data suggest Big Pharma paid more for clinically advanced assets while maintaining a wider sourcing funnel across earlier-stage opportunities.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026. Stage of lead asset in multi-asset deals.

Oncology licensing economics remained strongest for later-stage assets

IN-LICENSING BY BIG PHARMA: MEDIAN DEAL PAYMENTS AND NUMBER OF DEALS DISCLOSING VALUES BY STAGE AT SIGNING, ONCOLOGY ASSETS, 2024 TO Q3 2026¹



Across oncology licensing deals signed from 2024 through Q3 2026, median upfront payments generally increased with clinical maturity, rising from \$50 million for platform and discovery-stage assets to \$700 million for Phase III programs.


Phase III oncology programs also generated the highest median total deal value at about \$1.9 billion, compared with \$1.3 billion and \$1.2 billion for Phase I and Phase II assets. Phase II programs carried the largest median milestone packages at nearly \$1.5 billion, highlighting the value placed on clinically advanced assets with additional development and commercialization milestones ahead.

Later-stage results reflect a smaller disclosed sample, including five Phase III deals with upfront values and six with total deal values. Platform and discovery-stage activity was broader but typically carried more modest median upfront commitments.


Note: ¹Financials based on disclosed figures. Not all deals disclose all payment terms. Data through Sept. 30, 2026. Stage of lead asset in multi-asset deals.

China-origin assets retained a substantial share of big pharma licensing


GLOBAL LARGE-CAP BIOPHARMA IN-LICENSING FROM CHINESE BIOPHARMA:
DEALS WITH AT LEAST \$50 MILLION PAID UP FRONT



SHARE OF GLOBAL BIG PHARMA DEALS W/ \$50M+ UPFRONT ORIGINATING FROM CHINA



SHARE OF GLOBAL BIG PHARMA UPFRONTS OVER \$50M+ PAID TO CHINESE BIOPHARMA



China-origin licensing deals with upfront consideration of at least \$50 million totaled 18 through Q3 2026, nearly matching the 19 transactions recorded in 2025. Disclosed upfront cash and equity reached \$5.7 billion, above the \$5.1 billion reported last year.


China-origin assets represented 51% of global big pharma licensing deals carrying upfront payments of at least \$50 million, continuing a steady increase from 18% in 2023 and 39% in 2025.

The concentration was even greater by value: Chinese biopharma companies received 65% of upfront capital across these larger transactions, up from 36% in 2025. The gap between value and deal share suggests China-origin assets attracted larger upfront commitments on average.


Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026. Deals among global large-cap biopharma and Chinese domiciled biopharma.

Biopharma M&A slowed in Q3, but year-to-date value surpassed 2025


NUMBER OF BIOPHARMA M&A DEALS AND UPFRONT CASH AND EQUITY^{1,2}



MEDIAN M&A UPFRONT CASH AND EQUITY^{1,2}



COUNT OF M&A DEALS BY ACQUIRED COMPANY TYPE^{1,2}



Biopharma M&A moderated in Q3, totaling \$31.1 billion across 32 deals, down from \$66.8 billion across 51 deals in Q2. Despite the quarterly slowdown, 2026 YTD value reached \$138.9 billion across 113 deals, surpassing the \$122.1 billion recorded in full-year 2025.

Median upfront cash and equity declined from \$765 million in Q2 to \$661 million in Q3 but remained the third-highest quarterly median since 2023, reflecting the continued presence of sizable transactions.


Notable Q3 acquisitions included Vertex's \$10 billion acquisition of Crinetics Pharmaceuticals, Eli Lilly's \$2.8 billion acquisition of Merida Biosciences and Novartis' acquisition of Myricx Bio, headquartered in London, for about \$1.5 billion.

Eli Lilly remained particularly active through Q3, announcing 13 transactions with aggregate reported value exceeding \$30 billion.


Notes: ¹Financials based on disclosed figures. Data through Sept. 30, 2026. ²Biopharma M&A with any buyer type, acquisition options, and reverse mergers.

Later-stage and approved targets commanded substantial M&A premiums

SHARE OF BIOPHARMA M&A BY TARGET COMPANY STAGE AT ACQUISITION^{1,2}



MEDIAN M&A UPFRONT CASH AND EQUITY BY TARGET COMPANY STAGE, 2021 TO Q3 2026
LARGE-CAP (\$50B+) BIOPHARMA BUY-SIDE^{1,2}



Phase II, Phase III and approved-stage companies accounted for approximately 69% of biopharma-to-biopharma M&A deals through Q3 2026, maintaining the market's concentration in more clinically advanced targets.


Across transactions announced since 2021, median upfront cash and equity increased considerably with development stage, from \$226 million for platform and discovery companies to \$3.7 billion for Phase III targets and \$9.1 billion for approved-stage companies.

The data suggest the most pronounced valuation step-up occurs between preclinical and Phase I, where median consideration increases more than threefold, from \$314 million to \$1 billion. This may reflect the premium acquirers place on initial clinical validation, with median values continuing to rise as targets advance toward commercialization.

Notes: ¹Financials based on disclosed figures. Data through Sept. 30, 2026. ²Biopharma-to-Biopharma M&A, acquisition options, and reverse mergers.

Reverse mergers rebounded, with concurrent PIPEs accompanying most deals

BIOPHARMA THERAPEUTICS AND PLATFORMS REVERSE MERGERS WITH AND WITHOUT CONCURRENT PIPE FINANCINGS¹



Biopharma reverse-merger activity notched 27 transactions through Q3 2026, more than doubling the 12 deals recorded in full-year 2025. Disclosed transaction value totaled \$7.5 billion, below 2025’s \$9.8 billion but the third-highest annual total shown since 2017.


Concurrent private investments in public equity (PIPEs) accompanied 19 reverse mergers, or about 70% of transactions, compared with three deals in 2025. That represents the largest number of PIPE-supported reverse mergers in the period shown and the highest share since 2021.

The rebound suggests reverse mergers remain an active alternative route to the public markets, with PIPE capital frequently providing additional financing alongside the transaction.

Note: ¹Financials based on disclosed figures. Data through Sept. 30, 2026.

Biopharma IPO activity reached its strongest level since 2021

NASDAQ AND NYSE COMPLETED IPOs IN BIOPHARMA THERAPEUTICS AND PLATFORMS: TOTALS (\$B) AND COUNT^{1,2}



Notes: ¹Financials based on disclosed figures. Data through Sept. 30, 2026. ²Includes only Nasdaq and NYSE IPOs over \$15 million. Excludes Kenvue, Inc. (Q2 2023, \$4.4B) and other OTC focused companies. IPOs by completion date.

Biopharma IPOs on Nasdaq and the NYSE raised \$7.5 billion across 22 offerings through Q3 2026, exceeding each full-year total from 2022 through 2025 in both proceeds and offering count.

Average proceeds reached approximately \$339 million per offering, supported by several sizable transactions. Parabilis Medicines completed the year’s largest biopharma IPO at more than \$770 million.

Notable Q3 offerings included ADARx Pharmaceuticals’ \$446 million IPO and Braveheart Bio’s \$440 million IPO. Beyond Nasdaq and the NYSE, an additional five biopharma companies completed IPOs on the Hong Kong Stock Exchange.

Chase, J.P. Morgan, JPMorgan, JPMorgan Chase, and Story by J.P. Morgan are marketing names for certain businesses of JPMorgan Chase & Co. and its affiliates and subsidiaries worldwide (collectively, "JPMC", "We", "Our" or "Us", as the context may require). The information in this content (website, article, event invitation or other form) does not represent an offer or commitment to provide any product or service. The views, opinions, analyses, estimates and strategies, as the case may be ("views"), expressed in this content are those of the respective authors and speakers named in those pieces, and/or the JPMC departments that publish the content and may differ from those of JPMorgan Chase Commercial Banking and/or other JPMC employees and affiliates. These views are as of a certain date and often based on current market conditions, and are subject to change without notice. Any examples used are generic, hypothetical and for illustration purposes only. Any prices/quotes/statistics included have been obtained from sources deemed to be reliable, but we do not guarantee their accuracy or completeness. To the extent indices have been used in this content, please note that it is not possible to invest directly in an index. This is not a product of the Research Department of J.P. Morgan Securities LLC. This information in no way constitutes research and should not be treated as such. Any information related to cybersecurity provided is intended to help clients protect themselves from cyber fraud, not to provide a comprehensive list of all types of cyber fraud activities nor to identify all types of cybersecurity best practices.

Copying, re-publishing, or using this material or any of its contents for any other purpose is strictly prohibited without prior written consent from JPMorgan. In preparing this material, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information that was acquired from public sources. Any mentions of third-party trademarks, brand names, products and services are for referential purposes only and any mention thereof is not meant to imply any sponsorship, endorsement, or affiliation unless otherwise noted. Notwithstanding anything to the contrary, the statements in this material are not intended to be legally binding. Any products, services, terms or other matters described herein (other than in respect of confidentiality) are subject to, and superseded by, the terms of separate legally binding documentation and/or are subject to change without notice.

The information in this content is not advice on legal, tax, investment, accounting, regulatory, technology or other matters. You should always consult your own financial, legal, tax, accounting or similar advisors before making any financial or investment decisions, or entering into any agreement for JPMC products or services. In no event shall JPMC or any of its directors, officers, employees or agents be liable for any use of, for any decision made or action taken in reliance upon, or for any inaccuracies or errors in or omissions from, the information in this content. We are not acting as your or any client's agent, fiduciary or advisor, including, without limitation, as a Municipal Advisor under the Securities and Exchange Act of 1934. JPMC assumes no responsibility or liability whatsoever to you or any client with respect to such matters, and nothing herein shall amend or override the terms and conditions in the agreement(s) between JPMC and any client or other person.

The information in this content does not include all applicable terms or issues, and is not intended as an offer or solicitation for the purchase or sale of any product or service. Our products and services are subject to applicable laws and regulations, as well as our service terms and policies. Not all products and services are available in all geographic areas or to all customers. In addition, eligibility for particular products and services will be determined by JPMC, including satisfaction of applicable legal, tax, risk, credit and other due diligence, and JPMC's "know your customer", anti-money laundering, anti-terrorism and other policies and procedures. Credit is subject to approval. Rates and programs are subject to change. Certain restrictions apply.

Products and services may be provided by banking affiliates, securities affiliates or other JPMC affiliates or entities. In particular, securities brokerage services other than those that can be provided by banking affiliates will be provided by appropriate registered broker/dealer affiliates, including J.P. Morgan Securities LLC and J.P. Morgan Institutional Investments Inc. Any securities provided or otherwise administered by such brokerage services are not deposits or other obligations of, and are not guaranteed by, any banking affiliate and are not insured by the Federal Deposit Insurance Corporation. Certain financial products and services are required by law to be provided only by licensed representatives and affiliates. Inquiries regarding such products and services will be referred to a licensed representative or a licensed affiliate. The information in this content is not an offer to sell, or solicit an offer to purchase, any securities by anyone in any jurisdiction in which such offer or solicitation is not authorized, or in which JPMC or the person making such an offer is not qualified to do so, or to anyone to whom it is unlawful to make such an offer or solicitation, or to anyone in any jurisdiction outside of the United States. Nothing in this content constitutes any commitment by JPMC to underwrite, subscribe for or place any securities, or to extend or arrange credit, or to provide any other product or service. JPMC contact persons may be employees or officers of any JPMC subsidiary or affiliate.

Any information requested on this invitation, page or other relevant registration form will be processed for the purposes of preparation and administration of this event. Providing the requested information will also assist us in ensuring that the event is properly tailored to meet the requirements of the attendees. By providing the information requested, you are consenting to your data being processed by employees and agents of JPMC as well as potential co-organizers for these purposes. You expressly consent to our use of your information in the manner described herein and in our privacy policy (www.jpmorgan.com/privacy).

Please note that any JPMC-hosted event or webinar that you register to attend may be recorded, and videos, photographs and other recordings may be taken, where you may be captured participating in the event. By providing the information requested on the registration form, you consent to the publication of such photographs, videos, recordings and/or likenesses (whether edited, adapted, modified or copied), and their use by us and those that we authorize, without prior notice or compensation, in any way which we may see fit now or in the future, including but not limited to, marketing and advertising. Further, you release JPMC and its employees and agents from all claims of every kind on account of such use. You also acknowledge and agree that the replay links, if any, will be shared with JPMC clients and prospects who were invited but did not register/attend, and also potentially to other third parties if the topics are relevant to them. If you do not agree with any statements in this paragraph, please make a member of our staff aware on the day of the event.

The statements made in this content or during this event, or provided in materials as part of this event, are proprietary to JPMC and are not intended to be legally binding. Any products and services described during these events are offered by JPMC subject to applicable laws and regulations and service terms.

We will provide reasonable accessibility accommodations brought to our attention.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: <https://www.jpmorgan.com/IBOR>.

© 2026 JPMorgan Chase & Co. All rights reserved. JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A., organized under the laws of the U.S.A. with limited liability. Deposits held in non-U.S. branches, are not FDIC insured.